PARP1 and triple-negative breast carcinoma: Researches also elucidated that PARP inhibitor olaparib enhanced CD8+ T-cell recruitment and activation by activating the cGAS/STING pathway in BRCA1-deficient triple-negative breast cancer (Pantelidou et al., 2019).